Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Gillette

This article was originally published in The Rose Sheet

Executive Summary

Destocking initiatives "set stage for this year and beyond" but negatively impact second quarter net sales by 4%, Boston firm announces during July 20 conference call. Reported inventory levels of $1.38 bil. are 18.4% higher than levels at year-end. Blade and razor sales for the quarter fell 3% to $860 mil. despite strong sales of Venus and Mach3 shaving systems. Toiletry sales of $222 mil. fell 6% from the prior year period largely due to divestiture of White Rain hair care products. Consolidated sales in the quarter decreased 4.7% to $2.12 bil

Latest Headlines
See All
UsernamePublicRestriction

Register

RS009448

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel